Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Brookline Capital Markets Downgrades Tonix Pharma (TNXP) to Hold
July 27, 2018 10:04 AM EDTBrookline Capital Markets downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold.
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $3.95 yesterday.
... MoreUPDATE: B.Riley/FBR Downgrades Tonix Pharma (TNXP) to Neutral
July 27, 2018 10:04 AM EDT(Updated - July 30, 2018 9:04 AM EDT)
(updated to add analyst comment)
B.Riley/FBR downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.25 (from $8.00).
Analyst David Buck comments "We downgrade our rating for Tonix Pharmaceuticals Holding... More
Tonix Pharma (TNXP) Halted on LUDP
July 27, 2018 9:59 AM EDTTonix Pharma (NASDAQ: TNXP) Halted on LUDP
... More